MX9606450A - Derivados de bencimidazolona. - Google Patents

Derivados de bencimidazolona.

Info

Publication number
MX9606450A
MX9606450A MX9606450A MX9606450A MX9606450A MX 9606450 A MX9606450 A MX 9606450A MX 9606450 A MX9606450 A MX 9606450A MX 9606450 A MX9606450 A MX 9606450A MX 9606450 A MX9606450 A MX 9606450A
Authority
MX
Mexico
Prior art keywords
dopaminergic activity
central dopaminergic
benzimidazolone derivatives
derivatives
benzimidazolone
Prior art date
Application number
MX9606450A
Other languages
English (en)
Inventor
Anton F Fliri
Willian S Faraci
Mark A Sanner
Stevin H Zorn
Brian T O'neill
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX9606450A publication Critical patent/MX9606450A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/73Unsubstituted amino or imino radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta invencion se refiere a nuevos derivados farmacéuticamente activos de bencimidazolona, de formula (I), en la línea de puntos, R0 a R6 y X1 a Xa son como se han definido en la descripcion. Estos compuestos presentan actividad dopaminérgica central y son utiles en el tratamiento de trastornos del SNC.
MX9606450A 1994-06-14 1995-04-24 Derivados de bencimidazolona. MX9606450A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25970794A 1994-06-14 1994-06-14
PCT/IB1995/000285 WO1995034555A1 (en) 1994-06-14 1995-04-24 Benzimidazolone derivatives with central dopaminergic activity

Publications (1)

Publication Number Publication Date
MX9606450A true MX9606450A (es) 1997-03-29

Family

ID=22986031

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9606450A MX9606450A (es) 1994-06-14 1995-04-24 Derivados de bencimidazolona.

Country Status (11)

Country Link
EP (1) EP0765320B1 (es)
JP (1) JP2860604B2 (es)
AT (1) ATE206708T1 (es)
CA (1) CA2192975C (es)
DE (1) DE69523155T2 (es)
DK (1) DK0765320T3 (es)
ES (1) ES2163506T3 (es)
FI (1) FI113767B (es)
MX (1) MX9606450A (es)
PT (1) PT765320E (es)
WO (1) WO1995034555A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0953567A3 (en) 1998-04-29 2003-04-02 Pfizer Products Inc. Bicyclic substituted piperazine-, piperidine- and tetrahydropyridine derivatives, their preparation and their use as agents with central dopaminergic (dopamine D4 receptor) activity
HN1999000146A (es) * 1998-09-21 2000-11-11 Pfizer Prod Inc Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
EP1177792A3 (en) * 2000-07-27 2002-10-23 Pfizer Products Inc. Dopamine D4 Ligands for the treatment of novelty-seeking disorders
ES2273891T3 (es) * 2000-09-19 2007-05-16 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Nuevos derivados de bencimidazolona que presentan actividad en los receptores de serotonina y dopamina.
US6586435B2 (en) 2000-09-19 2003-07-01 Boehringer Ingelheim Pharma Kg Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors
US7183410B2 (en) 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
JP2004123562A (ja) * 2002-09-30 2004-04-22 Japan Science & Technology Corp 神経細胞死抑制作用を有する化合物を用いた医薬
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
CA2617546C (en) 2005-08-03 2014-07-15 Boehringer Ingelheim International Gmbh Use of flibanserin in the treatment of obesity
WO2007048803A1 (en) 2005-10-29 2007-05-03 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
TWI389889B (zh) 2006-05-09 2013-03-21 Targacept Inc (2s)-(4e)-n-甲基-5-〔3-(5-異丙氧基吡啶)基〕-4-戊烯-2-胺之新穎多晶型
WO2007134038A2 (en) 2006-05-09 2007-11-22 Astrazeneca Ab Salt forms of (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine
ES2336719T3 (es) 2006-06-30 2010-04-15 Boehringer Ingelheim International Gmbh Flibanserina para el tratamiento de la incontinencia urinaria y las enfermedades relacionadas.
AU2007286288A1 (en) 2006-08-14 2008-02-21 Boehringer Ingelheim International Gmbh Formulations of flibanserin and method for manufacturing the same
EA200900270A1 (ru) 2006-08-25 2009-08-28 Бёрингер Ингельхайм Интернациональ Гмбх Системы регулируемого высвобождения и способ их приготовления
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
AU2011256866B2 (en) 2010-05-20 2014-05-22 Astrazeneca Ab New process for the preparation of aryl substituted olefinic amines
JP2018112616A (ja) 2017-01-10 2018-07-19 富士フイルム株式会社 積層体、積層体の製造方法、および車両用ルームミラー
CN115836054A (zh) * 2020-05-06 2023-03-21 默沙东有限责任公司 Il4i1抑制剂和使用方法
CA3211341A1 (en) * 2021-03-19 2022-09-22 Centre National De La Recherche Scientifique Applications of biased ligands of the serotonin 5-ht7 receptor for the treatment of pain, multiple sclerosis and the control of thermoregulation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone

Also Published As

Publication number Publication date
WO1995034555A1 (en) 1995-12-21
EP0765320A1 (en) 1997-04-02
JPH09506637A (ja) 1997-06-30
FI113767B (fi) 2004-06-15
CA2192975C (en) 1999-09-21
PT765320E (pt) 2002-02-28
DE69523155T2 (de) 2002-02-07
FI965021A (fi) 1996-12-13
EP0765320B1 (en) 2001-10-10
DK0765320T3 (da) 2001-11-26
ES2163506T3 (es) 2002-02-01
JP2860604B2 (ja) 1999-02-24
CA2192975A1 (en) 1995-12-21
FI965021A0 (fi) 1996-12-13
DE69523155D1 (de) 2001-11-15
ATE206708T1 (de) 2001-10-15

Similar Documents

Publication Publication Date Title
MX9606450A (es) Derivados de bencimidazolona.
MX9707980A (es) Derivados de 4-aminoquinazolina, composiciones que los contienen, y uso de los mismos.
ES2127946T3 (es) Antagonistas de neurocinina diazabiciclica.
PT804252E (pt) Agentes queladores metalicos que contem monoaminas diamidas e tiois
YU25399A (sh) 6-fenilpiridil-2-amino derivati korisni kao nos inhibitori
MY110110A (en) Pharmaceuticals in the treatment of gastrointestinal disorders, cardiovascular disorders and cns disorders
IL114754A0 (en) Benzimidazole derivatives
TW324662B (en) Benzamide-containing pharmaceutical composition
HK1018701A1 (en) Benzopyran derivatives having leukotriene-antagonistic action.
EP1032556A4 (en) PHARMACEUTICALLY EFFECTIVE COMPOUNDS AND METHODS OF THEIR APPLICATION
MX9403088A (es) Composiciones farmaceuticas que contienen deriva- dos de indol y metodos de uso.
AP9701075A0 (en) Spirocyclic dopamine receptor subtype ligands.
MX9604762A (es) Nuevas sulfonamidas y procedimiento para su preparacion.
HRP940210A2 (en) New imidazoloquinoxalinones their production and use
NO984651L (no) Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet
BG105549A (en) Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system
NO970498L (no) Benzimidazolderivater med dopaminergisk aktivitet
PL326631A1 (en) Compounds exhibiting haemoregulatory activity

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees